Chi-Med CEO: New NSCLC Data Boosts Prospects For cMET Inhibitor Savolitinib
Good additional data from trials of Chi-Med's savolitinib in non small cell lung cancer was presented at this year's AACR meeting which should help speed the cMET inhibitor's validation and eventual launch, the China-based group's CEO tells Scrip.
You may also be interested in...
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.